CDK4 and nasopharyngeal carcinoma: In NPC, CDK4/6i in co-treatment with alpelisib (PI3K inhibitor) [47], gemcitabine (antimetabolite) [21], and SAHA (HDAC inhibitor) [50] exerted antitumor effects on a preclinical animal model.